N-(1-naphthyl)-N'-(1-hydroxy-2,2-pentamethylene)propylthiourea | 956126-30-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(1-naphthyl)-N'-(1-hydroxy-2,2-pentamethylene)propylthiourea
• 英文别名: N-(1-naphthyl)-N'-(3-hydroxy-2,2-pentamethylenepropyl)thiourea；1-[[1-(Hydroxymethyl)cyclohexyl]methyl]-3-naphthalen-1-ylthiourea
• CAS: 956126-30-0
• 化学式: C₁₉H₂₄N₂OS
• 分子量: 328.478
• InChiKey: IEFKDUPVLWEJFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  76.4
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(1-naphthyl)-N'-(1-hydroxy-2,2-pentamethylene)propylthiourea 在 碘甲烷 、 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以86%的产率得到N-(naphthalen-1-yl)-2-oxa-4-azaspiro[5.5]undecan-3-imine
  参考文献：
  名称：

  2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 3: Synthesis and activity of isosteric analogs

  摘要：

  Structure-activity relationships and efforts to optimize the pharmacokinetic pro. le of isosteric analogs of 2-arylimino-5,6-dihydro-4H-1,3-thiazines as cannabinoid receptor agonists are described. Among those examined, compound 25 showed potent affinity for cannabinoid receptor 1 (CB1) and receptor 2 (CB2). This compound displayed oral bioavailability and analgesic activity. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.070
• 作为产物：
  描述：

  1-萘胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-(1-naphthyl)-N'-(1-hydroxy-2,2-pentamethylene)propylthiourea
  参考文献：
  名称：

  2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds

  摘要：

  Structure-activity; relationships and efforts to optimize the pharmacokinetic profile of a class of 2-arylimino-5,6-dihydro4H-1,3-thiazines as cannabinoid receptor agonists are described. Among the compounds examined, compound 14 showed potent affinity and high selectivity for CB2, and compound 23 showed potent affinities against CB1 and CB2. These compounds displayed oral bioavailability. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.099

文献信息

• 2-Naphthylimino-1,3-thiazine derivative
  申请人：Kai Hiroyuki

  公开号：US20060281738A1

  公开（公告）日：2006-12-14

  The formula (I): wherein each of R 2 and R 3 is, same or different, C2-C4 alkyl or the like; or R 2 and R 3 are taken together with the adjacent carbon atom to form a 5 to 8 membered non-aromatic carbocyclic ring; R 4 is C1-C6 alkyl or the like; X is an oxgen atom or a sulfur atom; A is the group of the formula: wherein R 1 is, same or different, alkyl or the like; W is C2-C6 alkylene which may contain an optionally substituted heteroatom(s) or the like; n is an integer of 0 to 7, a pharmaceutically acceptable salt, or a solvate thereof.

  公式（I）：其中R2和R3分别为C2-C4烷基或类似基团，可以相同也可以不同；或者R2和R3与相邻的碳原子结合形成一个5到8元非芳香烷环；R4为C1-C6烷基或类似基团；X为氧原子或硫原子；A为以下公式的基团：其中R1为烷基或类似基团，可以相同也可以不同；W为C2-C6亚烷基，可以含有一个可选的取代杂原子或类似基团；n为0到7的整数，或其药物可接受的盐或溶剂化物。
• 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1659117A1

  公开（公告）日：2006-05-24

  The formula (I): wherein each of R2 and R3 is, same or different, C2-C4 alkyl or the like; or R2 and R3 are taken together with the adjacent carbon atom to form a 5 to 8 membered non-aromatic carbocyclic ring; R4 is C1-C6 alkyl or the like; X is an oxgen atom or a sulfur atom; A is the group of the formula: wherein R1 is, same or different, alkyl or the like; W is C2-C6 alkylene which may contain an optionally substituted heteroatom(s) or the like; n is an integer of 0 to 7, a pharmaceutically acceptable salt, or a solvate thereof.

  式 (I)： 其中 R2 和 R3 相同或不同，各自为 C2-C4 烷基或类似物；或 R2 和 R3 与相邻碳原子一起形成 5 至 8 位元的非芳香族碳环；R4 为 C1-C6 烷基或类似物；X 为氧原子或硫原子；A 为式中的基团： 其中 R1 是相同或不同的烷基或类似物；W 是 C2-C6 亚烷基，可含有任选取代的杂原子或类似物；n 是 0 至 7 的整数、药学上可接受的盐或其溶液。
• EP1659117
  申请人：——

  公开号：——

  公开（公告）日：——
• US7482339B2
  申请人：——

  公开号：US7482339B2

  公开（公告）日：2009-01-27
• 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds
  作者：Hiroyuki Kai、Yasuhide Morioka、Minoru Tomida、Tadashi Takahashi、Maki Hattori、Kohji Hanasaki、Katsumi Koike、Hiroki Chiba、Shunji Shinohara、Toshiyuki Kanemasa、Yuka Iwamoto、Kohji Takahashi、Yoshitaka Yamaguchi、Takahiko Baba、Takayoshi Yoshikawa、Hideyuki Takenaka

  DOI：10.1016/j.bmcl.2007.04.099

  日期：2007.7

  Structure-activity; relationships and efforts to optimize the pharmacokinetic profile of a class of 2-arylimino-5,6-dihydro4H-1,3-thiazines as cannabinoid receptor agonists are described. Among the compounds examined, compound 14 showed potent affinity and high selectivity for CB2, and compound 23 showed potent affinities against CB1 and CB2. These compounds displayed oral bioavailability. (C) 2007 Elsevier Ltd. All rights reserved.